NCT07196280View on ClinicalTrials.gov

Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies

CompletedOBSERVATIONAL

Enrollment

10,000

Participants

Timeline

Start Date

January 1, 2012

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD)Benign Prostatic Hypertrophy (BPH)

Interventions

DRUG

5-Alpha Reductase Inhibitors

Building on prior studies, drug exposure was defined as receiving 5-ARIs on at least two separate occasions, with an interval of no more than 180 days between prescriptions. Based on exposure status, the cohort was stratified into two groups.

All Listed Sponsors

lead

Chinese PLA General Hospital

OTHER